Categories: News

Glow Lifetech Grants Stock Options

Toronto, Ontario–(Newsfile Corp. – December 27, 2024) – Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) (“Glow” or the “Company“) is pleased to announce that it has granted 3,650,000 stock options (the “Options”) to various officers and consultants of the Company. Each Option is exercisable at a price of $0.06 for one common share of the Company (each a “Common Share”) for a period of five years from the date of grant and are being issued under the terms of the Company’s Omnibus Long-Term Incentive Plan. The Options, and any Common Shares issued upon exercise of the Options, are subject to a four-month and one day resale restriction from the date of grant.

The aforementioned grant of Options resulted in certain insiders of the Company receiving an aggregate of 2,500,000 Stock Options. The Company has relied on the exemptions from the valuation and minority shareholder approval requirements of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), contained in section 5.5(b) and 5.7(a) of MI 61-101 in respect of such insider participation.

SUBSCRIBE: For more information on Glow or to subscribe to the Company’s mail list visit: https://www.glowlifetech.com/news

About Glow Lifetech Corp

Glow Lifetech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has a groundbreaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of the valuable compounds.

Website: www.glowlifetech.com

Contact:
James Van Staveren
Glow Lifetech Corp.
TF. 855-442-GLOW (4569)
ir@glowlifetech.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedarplus.ca

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/235305

Staff

Recent Posts

Judge Baker Children’s Center d/b/a The Baker Center for Children and Families Provides Notice of Data Security Incident

BOSTON, Dec. 27, 2024 /PRNewswire/ -- Judge Baker Children's Center d/b/a The Baker Center for…

10 hours ago

Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company

RA'ANANA, Israel, Dec. 27, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN), (NASDAQ:…

16 hours ago

In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI

CHONGQING, China, Dec. 27, 2024 /PRNewswire/ -- BGM Group Ltd. (Stock Code: BGM) has successfully acquired…

16 hours ago

NAVIGANTIS VASCO™ Robotic Platform Used with First Patients Enrolled in Neurovascular Study

MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases…

16 hours ago

Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand

Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without…

16 hours ago

Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…

19 hours ago